Medidata, owned by Dassault Systèmes, makes Rave, the most used electronic data capture system in clinical trials, plus randomisation and outcome-assessment tools and synthetic control arms built from past trial data. Whether regulators accept synthetic controls for oncology approvals is the open question.
Medidata, based in New York and acquired by Dassault Systèmes in 2019, makes Rave, the most used electronic data capture system in clinical trials, and offers synthetic control arm services. Its products span Rave EDC, electronic clinical outcome assessment, randomisation and trial supply management, and Acorn AI for synthetic controls built from past trial data. OnCo links it to clinical trial software covering EDC, eCOA, CTMS and RTSM. Whether synthetic control arms drawn from historical trial data will be accepted by regulators for oncology approvals is the open question. The clinical trial software page carries the wider picture.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag supporting.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag supporting.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Shares Clinical trial software (EDC, eCOA, CTMS, RTSM) and the tag supporting.
Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
The electronic data capture system a large share of oncology trials are run in, with the randomisation and supply modules around it.